The current study demonstrated the superior in vivo antitumor activity of the association between Salvia officinalis L. and Doxorubicin as compared with Doxorubicin alone and its lack of toxicity. The study was carried out on 32 Mus musculus female mice, for 14 days long. The tumor model was Ehrlich Ascites Carcinoma (EAC). Animals were divided in four equal groups of 8 mice: normal control, tumor control, EAC + doxorubicin and EAC + doxorubicin + Salvia officimalis L. All the values that reflect the tumor development (difference in body weight, EAC volume and cellular concentration) were improved in significant manner. Hematological and biochemistry parameters determination were performed for all four groups of mice and no cytotoxicity was found. The efficacy of Salvia officinalis L. as an adjuvant therapy in cancer has been demonstrated
